News and Trends 3 Oct 2022 Poxel granted orphan drug designation for kidney disease treatment French biopharma company Poxel SA says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator – and is also a phase 2 ready ADPKD asset, subject […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. The deal could eventually be worth upwards of $1.4 billion. Its lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 AmplifyBio acquires PACT Pharma assets AmplifyBio has acquired select assets from PACT Pharma, Inc., a privately held biopharmaceutical company developing neoantigen-specific T cell receptor cell therapies. The deal will provide AmplifyBio with advanced characterization platforms, bioinformatics capabilities, and 40 drug development experts to enhance its own cell and gene therapy service offerings. AmplifyBio will also acquire the South San Francisco […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Redx presents data confirming anti-fibrotic effects of lung disease drug Redx Pharma has announced preclinical efficacy data in immune mediated models for RXC007. The data on RXC007, its lead fibrosis asset, was presented alongside encouraging final phase 1 safety and pharmacokinetic data at the International Colloquium on Lung and Airway Fibrosis (ICLAF) on October 2 by Nicolas Guisot, research fellow at Redx Pharma. The data […] October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Roche launches next-generation SARS-CoV-2 Rapid Antibody Test Roche has launched the SARS-CoV-2 Rapid Antibody Test 2.0 in markets accepting the CE Mark. The test is the next generation of Roche’s existing SARS-CoV-2 Rapid Antibody Test, which launched in July 2020. The SARS-CoV-2 Rapid Antibody Test 2.0 offers broader use than its original configuration, which focused on recovered patients, to now include vaccinated […] October 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2022 Treatment for hot flushes and night sweats accepted for regulatory review by EMA A treatment for moderate to severe vasomotor symptoms (VMS) has been accepted by the European Medicines Agency (EMA) for regulatory review. Astellas Pharma Inc., submitted a marketing authorization application (MAA) for fezolinetant, an investigational oral, nonhormonal compound. VMS is characterized by hot flushes and/or night sweats which are common menopausal symptoms. Hot flushes The news […] September 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2022Beyond Biotech podcast 16: Adocia, Omnio, Phenomix Sciences, Tridek-One This week, we have four guests: Olivier Soula, deputy-CEO and director of R&D at Adocia; Ulrika Norin, CEO of Omnio; Mark Bagnall, CEO of Phenomix Sciences; and Laurence de Schoulepnikoff, CEO of Tridek-One. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored […] September 30, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Kling Biotherapeutics doses first patient in advanced solid tumor trial Kling Biotherapeutics BV has dosed the first patient with KBA1412 in its phase 1b trial to evaluate the safety, tolerability, PK/PD, and potential efficacy of KBA1412 in adult patients with advanced solid tumors not responding to standard of care. KBA1412 is a first in class fully human anti-CD9 antibody based on an antibody produced by […] September 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 European Science Park Group creates specialized space for innovative industries ESPG AG – European Science Park Group – is one of the first German real estate companies to specialize in the ownership, management and acquisition of science parks. A science park is a concept that originated in the U.S. and has already developed into its own asset class in the U.K. and other European countries. […] September 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Umeå Biotech Incubator launches international coaching program The Umeå Biotech Incubator (UBI) in Sweden specializes in developing life science business ideas. Now it is launching an international incubator program. “If you strive to be one of the world’s best incubators you must have the whole world as your marketplace,” said Jennie Ekbeck, CEO of Umeå Biotech Incubator. Umeå Biotech Incubator was founded […] September 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 NeuShen Therapeutics closes $20M pre-A financing Chinese biotech company NeuShen Therapeutics, Inc. has closed an approximately $20 million series pre-A financing led by LAPAM, a China based venture capital. The new capital will be used to expand the team and catalyze in-house CNS (central nervous system) drug discovery in both the U.S. and China. “The successful completion of this fundraising is […] September 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 29 Sep 2022 Removing binding sites for an oncogene can slow cancer cell growth, researchers say Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […] September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email